James Kihara sold $68k of ACAD
PRINCIPAL ACCOUNTING OFFICER at ACADIA PHARMACEUTICALS INC. 4,073 shares at an average of $16.81, traded Nov 19, 2024, filed Nov 19, 2024.
Score components
- +15RoleOfficer
- +8Trade size$68k at market
- +5Share of holdings soldSold 17% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +3.2%, 3m +21.8%, 6m +33.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-027293, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 17, 2024 | MOption exercise Common Stock | +3,965 | - | - | 19,971 | Nov 19, 2024 |
| Nov 17, 2024 | MOption exercise Common Stock | +3,965 | - | - | 23,936 | Nov 19, 2024 |
| Nov 19, 2024 | SOpen-market sale Common Stock10b5-1 | -4,073 | $16.81 | $68k | 19,863 | Nov 19, 2024 |
| Nov 17, 2024 | MOption exercise Restricted Stock Unitsderivative | -3,965 | $0.00 | $0 | 3,966 | Nov 19, 2024 |
| Nov 17, 2024 | MOption exercise Restricted Stock Unitsderivative | -3,965 | $0.00 | $0 | 3,966 | Nov 19, 2024 |
Related signals
Other insiders at ACADIA PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 10Weak | ACADIA PHARMACEUTICALS INC | James Kihara PRINCIPAL ACCOUNTING OFFICER | $97k 4,084 shares | -14% | |
| 20Weak | ACADIA PHARMACEUTICALS INC | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | $243k 10,262 shares | -16% | |
| 70Notable | ACADIA PHARMACEUTICALS INC | James M Daly director | $671k 30,000 shares | -88% | |
| 19Weak | ACADIA PHARMACEUTICALS INC | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | $83k 3,498 shares | -7% | |
| 29Weak | ACADIA PHARMACEUTICALS INC | Elizabeth A. Garofalo director | $42k 1,600 shares | -6% | |
| 31Weak | ACADIA PHARMACEUTICALS INC | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | $554k 22,000 shares | -35% | |
| 39Weak | ACADsell ACADIA PHARMACEUTICALS INC | Laura Brege director | $315k 14,446 shares | -49% | |
| 17Weak | ACADIA PHARMACEUTICALS INC | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | $50k 2,000 shares | -3% | |
| 17Weak | ACADIA PHARMACEUTICALS INC | James Kihara PRINCIPAL ACCOUNTING OFFICER | $90k 4,000 shares | -16% | |
| 2Weak | ACADIA PHARMACEUTICALS INC | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | $51k 3,498 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.